Tag Archives: retogatein

Kailera Valued at $1.9B as it Eyes IPO; Diamyd Discontinues DIAGNODE-3 Trial

Two cardiometabolic-related news items have been observed: Kailera Therapeutics released its IPO pricing (view SEC filing) and Diamyd Medical discontinued its Ph3 DIAGNODE-3 trial evaluating retogatein (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Kailera Files IPO; Diamyd Data Disappoints; Insilico and Lilly Partner for AI Drug Discovery; EMA Approves Bayer’s Kerendia for HFpEF; Gan & Lee QW Insulin; Roche Ph1 CAD Study; Lilly Ph3 TOGETHER-PsA Results

A series of cardiometabolic-related news items has been observed from Kailera Therapeutics, Diamyd Medical, Insilico, Bayer, Gan & Lee Pharmaceuticals, Roche, and Lilly. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here